Research areas and methodologies


  • Preclinical and clinical evaluation of cardiovascular toxicity induced by approved or investigational anticancer drugs (anthracyclines, anthracenediones, taxanes, tyrosine kinase inhibitors with activity on FLT3++ acute myeloid leukemia, Ph++ T315I+/--acute lymphoblastic leukemia,+ T315I+/-chronic myeloid leukemia, indoleamine 2,3-dioxygenase inhibitors)
  • Pharmacokinetics of tyrosine kinase inhibitors in hematological patients
  • Pharmacokinetics of antifungal drugs in hematological patients
  • Development and validation of analytical methods for Therapeutic Drug Monitoring


  • In vitro translational model of human heart exposed to clinically relevant concentrations of drugs and/or drug combinations for monitoring cardiac pharmacokinetics and metabolism
  • cell lines
  • cell lines and cell-free systems for structure-activity and metabolism studies
  • Hematological and oncological patients at risk of cardiovascular events during chemotherapy regimens
  • Hematological patients at risk of pharmacokinetic interactions between antifungals and tyrosine kinase inhibitors


  • Cell culture and tissue samples
  • UV/VIS/NIR spectroscopy
  • High Performance Lquid Chromatography
  • Tandem Mass Spectrometry
  • Good Laboratory Practices and Good Clinical Practices

Collaborations with other Research Centers

  • Abramson Cancer Center, Philadelphia, PA
  • University of Pennsylvania School of Medicine, Philadelphia, PA
  • MD Anderson Cancer Institute, Houston, TX
  • IRCCS Fondazione Policlinico Gemelli, Rome
  • University of Tor Vergata, Rome


Methods for reducing toxicity of combined chemotherapies

  • LD0226 (co-sharing with Bristol Myers Squibb, USA)
  • LD0231 (co-sharing with Bristol Myers Squibb, USA)


  1. PRABB, Preclinical Pharmacology laboratory
  2. Campus Bio-Medico University Hospital Foundation, Clinical Pharmacology laboratory